ライフサイエンスコーパス: Roux-en-Y gastric bypass

1 adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass.

2 from the changes seen in weight loss without Roux-en-Y gastric bypass.

3 col and 60 were randomly assigned to undergo Roux-en-Y gastric bypass.

4 the duodenal-jejunal bypass component of the Roux-en-Y gastric bypass.

5 ared to the laparoscopic gastric band or the Roux-en-Y gastric bypass.

6 r reduced drug bioavailability 1 month after Roux-en-Y gastric bypass.

7 The most commonly performed operation is Roux-en-Y gastric bypass.

8 operations, the majority being laparoscopic Roux-en-Y gastric bypass.

9 abetes, hypertension, and dyslipidemia after Roux-en-Y gastric bypass.

10 e treatment and of adult controls undergoing Roux-en-Y gastric bypass.

11 scopic adjustable gastric banding to 76% for Roux-en-Y gastric bypass.

12 , and a combination of both methods, such as Roux-en-Y gastric bypass.

13 Patients undergoing Roux-en-Y gastric bypass (161 participants) or sleeve ga

14 rdized procedure for mouse and rat models of Roux-en-Y gastric bypass (80-90 min operative time) and

15 he most widely performed surgical procedure, Roux-en-Y gastric bypass, achieves permanent (followed u

16 ve demonstrated the overall effectiveness of Roux-en-Y gastric bypass, adjustable gastric banding, an

17 , 42-51]; 78% women): 1513 who had undergone Roux-en-Y gastric bypass and 509 who had undergone lapar

18 Roux-en-Y gastric bypass and biliopancreatic diversion c

19 conventional bariatric operations-especially Roux-en-Y gastric bypass and laparoscopic adjustable gas

20 ost commonly performed bariatric procedures, Roux-en-Y gastric bypass and laparoscopic adjustable gas

21 Roux-en-Y gastric bypass and SG are associated with comp

22 in patients who have undergone laparoscopic Roux-en-Y gastric bypass and to develop decision tree mo

23 Bariatric surgeries, such as Roux-en-Y gastric bypass and vertical sleeve gastrectomy

24 nderstanding of the microbiome changes after Roux-en-Y gastric bypass and weight loss; and (3) a basi

25 t of Bariatric Surgery (85 women underwent a Roux-en-Y gastric bypass, and 21 women underwent laparos

26 the safety and efficacy of the laparoscopic Roux-en-Y gastric bypass, and several papers address the

27 es with the excluded biliopancreatic limb in Roux-en-Y gastric bypass, and this may provide a novel e

28 de cholangiopancreatography in patients with Roux-en-Y gastric bypass are discussed.

29 Although vertical banded gastroplasty and Roux-en-Y gastric bypass are the two procedures most com

30 13-18 years) with severe obesity undergoing Roux-en-Y gastric bypass at three specialised paediatric

31 hrelin were reduced after VSG, but not after Roux-en-Y gastric bypass, based on enzyme-linked immunos

32 bariatric surgery were offered laparoscopic Roux-en-Y gastric bypass between July 1997 and March 200

33 Roux-en-Y gastric bypass can be successfully performed i

34 nt (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce remarkable health

35 Roux-en-Y gastric bypass causes increased secretion of g

36 uding bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), colorectal surgery (colectomy

37 Approximately 11 % of patients who underwent Roux-en-Y gastric bypass develop symptomatic gallstone d

38 t of young people aged 13-21 years underwent Roux-en-Y gastric bypass for clinically severe obesity a

39 cal Data Base for all patients who underwent Roux-en-Y gastric bypass for the treatment of morbid obe

40 Laparoscopic Roux-en-Y gastric bypass for weight loss is being perfor

41 f the endocrine system in patients following Roux-en-Y gastric bypass (GBP) are poorly described and

42 In all years, laparoscopic Roux-en-Y gastric bypass generated the highest number of

43 : Adolescents with severe obesity undergoing Roux-en-Y gastric bypass had substantial weight loss ove

44 Roux-en-Y gastric bypass has a higher complication rate

45 h the ideal procedure has yet to be devised, Roux-en-Y gastric bypass has proved to be successful for

46 %) in 3-year percent weight change following Roux-en-Y gastric bypass, ie, weekly self-weighing, cont

47 The authors attempted total laparoscopic Roux-en-Y gastric bypass in 281 consecutive patients.

48 to analyse long-term (>5 years) outcomes of Roux-en-Y gastric bypass in a cohort of young adults who

49 ential predictor of diabetes remission after Roux-en-Y gastric bypass in obesity.

50 nd February, 2007, 74 young people underwent Roux-en-Y gastric bypass in the FABS study.

51 We performed Roux-en-Y gastric bypass in two morbidly obese patients

52 treated adolescents and of adults undergoing Roux-en-Y gastric bypass, in the Adolescent Morbid Obesi

53 Complications after Roux-en-Y gastric bypass include anastomotic leaks and s

54 Roux-en-Y gastric bypass induced significantly greater w

55 The Roux-en-Y gastric bypass is a highly successful approach

56 Laparoscopic Roux-en-Y gastric bypass is a new and technically challe

57 Although weight loss following Roux-en-Y gastric bypass is acceptable in patients with

58 Laparoscopic Roux-en-Y gastric bypass is effective in achieving weigh

59 ing from microbial sequencing analyses after Roux-en-Y gastric bypass is the comparative overabundanc

60 A Roux-en-Y gastric bypass is the procedure of choice when

61 ic procedures performed include laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastri

62 laparoscopic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass, laparoscopic gastric band plac

63 goal length of stay (LOS) after laparoscopic Roux-en-Y gastric bypass (LRYGB) should be 1 day to impr

64 en-y gastric bypass (ORYGB) and laparoscopic roux-en-y gastric bypass (LRYGB) were common pre-NCD (56

65 id-term results comparable with laparoscopic roux-en-y gastric bypass (LRYGB) with an improved safety

66 the current standard procedure, laparoscopic Roux-en-Y gastric bypass (LRYGB).

67 recruited to the study, of whom 81 underwent Roux-en-Y gastric bypass (mean age 16.5 years [SD 1.2],

68 Roux-en-Y gastric bypass (n = 161), sleeve gastrectomy (

69 ow-up of 6 years (range: 5-9) after surgery (Roux-en-Y gastric bypass, n = 162; gastric banding, n =

70 orbid obesity and who underwent laparoscopic Roux-en-Y gastric bypass, open Roux-en-Y gastric bypass,

71 Adults having had a laparoscopic Roux-en-Y gastric bypass or a laparoscopic vertical slee

72 ceive either medical treatment or surgery by Roux-en-Y gastric bypass or biliopancreatic diversion.

73 al therapy alone versus medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 ob

74 of consecutive patients scheduled to undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three

75 rapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

76 rapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

77 dence of symptomatic gallstone disease after Roux-en-Y gastric bypass or sleeve gastrectomy.

78 Open roux-en-y gastric bypass (ORYGB) and laparoscopic roux-e

79 Patients were randomized to Roux-en-Y gastric bypass plus medical therapy or medical

80 % CI, 1.04-1.15]; P = .01), and undergoing a Roux-en-Y gastric bypass procedure (AOR, 2.07 [95% CI, 1

81 ower interpersonal support) and undergoing a Roux-en-Y gastric bypass procedure.

82 The Roux-en-Y gastric bypass produced greater weight loss, H

83 Roux-en-Y Gastric Bypass remains an excellent and durabl

84 Roux-en-Y gastric bypass reversed all of these DIO-induc

85 edures [i.e., a sleeve gastrectomy, proximal Roux-en Y gastric bypass (RYGB), and distal RYGB].

86 from approximately 1000 patients undergoing Roux-en-Y gastric bypass (RYGB) and clinical traits asso

87 Laparoscopic Roux-en-Y gastric bypass (RYGB) and laparoscopic adjusta

88 Roux-en-Y gastric bypass (RYGB) and laparoscopic adjusta

89 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (

90 Roux-en-Y gastric bypass (RYGB) and vertical sleeve gast

91 Rapid glycemic improvements following Roux-en-Y gastric bypass (RYGB) are frequently attribute

92 its development and ultimate remission after Roux-en-Y gastric bypass (RYGB) are not fully understood

93 The antidiabetes effects of Roux-en-Y gastric bypass (RYGB) are well-known, but the

94 al effectiveness and long-term durability of Roux-en-Y Gastric Bypass (RYGB) at an accredited center.

95 The resolution of type 2 diabetes after Roux-en-Y gastric bypass (RYGB) attests to the important

96 e, clinical cohort of veterans who underwent Roux-en-Y gastric bypass (RYGB) compared with nonsurgica

97 lean and obese controls, patients following Roux-en-Y gastric bypass (RYGB) had increased postprandi

98 Improvement in type 2 diabetes after Roux-en-Y gastric bypass (RYGB) has been attributed part

99 Revisional laparoscopic surgery after Roux-en-Y gastric bypass (RYGB) has been linked to subst

100 -1) to postprandial glucose metabolism after Roux-en-Y gastric bypass (RYGB) has been the subject of

101 Roux-en-Y gastric bypass (RYGB) improves glucose homeost

102 BACKGROUND & AIMS: Roux-en-Y gastric bypass (RYGB) improves glucose homeost

103 Roux-en-Y gastric bypass (RYGB) improves glycemic contro

104 pared these to the early and late effects of Roux-en-Y gastric bypass (RYGB) in 22 patients with T2D

105 re we developed the first published model of Roux-en-Y gastric bypass (RYGB) in female rats.

106 n 352 patients (mean BMI 45.8); 6 studies of Roux-en-Y gastric bypass (RYGB) included 131 patients (m

107 Roux-en-Y gastric bypass (RYGB) involves exclusion of ma

108 Roux-en-Y gastric bypass (RYGB) is an effective treatmen

109 Weight regain or insufficient loss after Roux-en-Y gastric bypass (RYGB) is common.

110 BACKGROUND AND AIMS: Hyperoxaluria after Roux-en-Y gastric bypass (RYGB) is generally attributed

111 Roux-en-Y gastric bypass (RYGB) is highly effective in r

112 Roux-en-Y gastric bypass (RYGB) is the most common baria

113 The effect of a Roux-en-Y gastric bypass (RYGB) on body weight has been

114 providing further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control

115 influence of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bar

116 rded Current Procedural Terminology code for Roux-en-Y gastric bypass (RYGB) or adjustable gastric ba

117 Three years after Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustab

118 ents in pain and physical function following Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustab

119 type 2 diabetes mellitus were randomized to Roux-en-Y gastric bypass (RYGB) or to hypocaloric diet (

120 Bariatric procedures, such as Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastr

121 Roux-en-Y gastric bypass (RYGB) produces substantial bod

122 Roux-en-Y gastric bypass (RYGB) reduces body weight and

123 Roux-en-Y gastric bypass (RYGB) restricts food intake, a

124 r time in drug use among patients undergoing Roux-en-Y gastric bypass (RYGB) surgery and a matched po

125 Both Roux-en-Y gastric bypass (RYGB) surgery and exercise can

126 Existing mouse models of Roux-en-Y gastric bypass (RYGB) surgery are not comparab

127 e mechanisms of metabolic improvements after Roux-en-Y gastric bypass (RYGB) surgery are not entirely

128 studies on the prevalence of symptoms after Roux-en-Y gastric bypass (RYGB) surgery are sparse.

129 Roux-en-Y gastric bypass (RYGB) surgery causes profound

130 The amount of weight loss attained after Roux-en-Y gastric bypass (RYGB) surgery follows a wide a

131 morbid disease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesi

132 ins on type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery for patients tak

133 bjects increased their improvement following Roux-en-Y gastric bypass (RYGB) surgery in hepatic and s

134 Roux-en-Y gastric bypass (RYGB) surgery is an effective

135 pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated wi

136 Roux-en-Y gastric bypass (RYGB) surgery is one of the mo

137 oscopic adjustable gastric banding (LAGB) or Roux-en-Y gastric bypass (RYGB) surgery on the metabolic

138 ts with type 2 diabetes mellitus who undergo Roux-en-Y gastric bypass (RYGB) surgery or standard medi

139 Roux-en-Y gastric bypass (RYGB) surgery results in exagg

140 o acids (BCAAs) after weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery than after calor

141 uptake and metabolism are upregulated after Roux-en-Y gastric bypass (RYGB) surgery, which contribut

142 re reversed following weight loss induced by Roux-en-Y gastric bypass (RYGB) surgery.

143 n response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery.

144 s durability of the efficacy associated with Roux-en-Y gastric bypass (RYGB) surgery.

145 se disorders can be improved or prevented by Roux-en-Y gastric bypass (RYGB) surgery.

146 or risk factors associated with mortality in Roux-en-Y gastric bypass (RYGB) surgery.

147 Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable

148 cluding gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), modified RYGB (mRYGB) a

149 hanisms for improved glucose tolerance after Roux-en-Y gastric bypass (RYGB).

150 atic diversion with duodenal switch (DS) and Roux-en-Y Gastric Bypass (RYGB).

151 c hypoglycemia (PHH) is often reported after Roux-en-Y gastric bypass (RYGB).

152 ical factors and long-term weight loss after Roux-en-Y gastric bypass (RYGB).

153 predictive markers for T2DM remission after Roux-en-Y gastric bypass (RYGB).

154 s of apolipoprotein A-IV (apoA-IV) rise with Roux-en-Y gastric bypass (RYGB).

155 gastroplasty/banding (GP/B): all revised to Roux-en-Y gastric bypass (RYGB); and 66 gastric bypass:

156 ic neurotransmission would be enhanced after Roux-en-Y-Gastric Bypass (RYGB) and Vertical Sleeve Gast

157 rvention for 2 years or surgical treatments (Roux-en-Y gastric bypass [RYGB] or laparoscopic adjustab

158 Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy

159 emarkable remission of type 2 diabetes after Roux-en-Y gastric bypass (RYGBP) are still puzzling.

160 y the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGBP) on heme- and nonheme-ir

161 Long-term health maintenance after Roux-en-Y gastric bypass should focus on adherence to di

162 re eligible for bariatric surgery, including Roux-en-Y gastric bypass, sleeve gastrectomy, or adjusta

163 atified by type of surgery (gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy, or other/u

164 cts of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries for obesity.

165 festyle and medical management plus standard Roux-en-Y gastric bypass surgery (gastric bypass).

166 Participants received either laparoscopic Roux-en-Y gastric bypass surgery (n = 100) or laparoscop

167 with type 2 diabetes mellitus shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there

168 Roux-en-Y gastric bypass surgery (RYGB) results in remis

169 nd effective treatment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB), which results i

170 Roux-en-Y gastric bypass surgery (RYGBP), the most commo

171 s with type 2 diabetes mellitus-1 managed by Roux-en-Y gastric bypass surgery and a comparable group

172 lated the benefits and harms of laparoscopic Roux-en-Y gastric bypass surgery in patients defined by

173 articular, patients who undergo laparoscopic Roux-en-Y gastric bypass surgery may be at increased ris

174 ion, participants who underwent laparoscopic Roux-en-Y gastric bypass surgery reported a significant

175 INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial

176 monstrated that after 10 years of follow-up, Roux-en-Y gastric bypass surgery, compared with nonsurgi

177 associated with diabetes remission following Roux-en-Y gastric bypass surgery, suggesting new therape

178 s treated with SRIs frequently relapse after Roux-en-Y gastric bypass surgery, the authors sought to

179 ntensive medical management intervention and Roux-en-Y gastric bypass surgery.

180 dogenous hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass surgery.

181 .5 (mean = 5.6) years) weight loss following Roux-en-Y gastric bypass surgery.

182 roups: 418 patients who sought and underwent Roux-en-Y gastric bypass (surgery group), 417 patients w

183 ts of an observational, prospective study of Roux-en-Y gastric bypass that was conducted in the Unite

184 Roux-en-Y gastric bypass, the most widely performed proc

185 rol and treatment risks 2 years after adding Roux-en-Y gastric bypass to intensive lifestyle and medi

186 Laparoscopic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, a

187 mum follow-up for LAGB was 54.2% EWL and for Roux-en-Y gastric bypass was 54.0% EWL.

188 Laparoscopic Roux-en-Y gastric bypass was consistently among the top

189 A Roux-en-Y gastric bypass was performed in morbidly obese

190 Roux-en-Y gastric bypass was the most common procedure.

191 y of patients who had undergone laparoscopic Roux-en-Y gastric bypass with surgically confirmed IH (n

192 tcomes of adolescent surgical patients after Roux-en-Y gastric bypass with those of conservatively tr